Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric S Daar

Showing results (111-120 of 222) with videos related to

Pageof 23
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 19, 2013
Shedding of HIV and human herpesviruses in the semen of effectively treated HIV-1-infected men who have sex with menSara Gianella, Davey M Smith, Milenka V Vargas, et al.
Journal of Virology|January 18, 2008
Primary human immunodeficiency virus type 1 (HIV-1) infection during HIV-1 Gag vaccinationArumugam Balamurugan, Martha J Lewis, Christina M R Kitchen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 21, 2013
Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabineKimberly Y Smith, Camlin Tierney, Katie Mollan, et al.
AIDS (London, England)|July 4, 2006
Cognitive-behavioral intervention to enhance adherence to antiretroviral therapy: a randomized controlled trial (CCTG 578)Glenn J Wagner, David E Kanouse, Daniela Golinelli, et al.
Virology|September 12, 2006
Lack of neutralizing antibody response to HIV-1 predisposes to superinfectionDavey M Smith, Matthew C Strain, Simon D W Frost, et al.
AIDS Research and Therapy|April 8, 2025
Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIVEric S Daar, Chloe Orkin, Paul E Sax, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 23, 2020
Initiation of Antiretroviral Therapy in the Hospital Is Associated With Linkage to Human Immunodeficiency Virus (HIV) Care for Persons Living With HIV and Substance Use DisorderPetra Jacobs, Daniel J Feaster, Yue Pan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 17, 2018
Safety and Impact of Low-dose Methotrexate on Endothelial Function and Inflammation in Individuals With Treated Human Immunodeficiency Virus: AIDS Clinical Trials Group Study A5314Priscilla Y Hsue, Heather J Ribaudo, Steven G Deeks, et al.
The Journal of Infectious Diseases|June 27, 2013
Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248Adriana Andrade, Susan L Rosenkranz, Anthony R Cillo, et al.
AIDS (London, England)|April 23, 2008
Comparison of algorithms that interpret genotypic HIV-1 drug resistance to determine the prevalence of transmitted drug resistanceLin Liu, Susanne May, Douglas D Richman, et al.
Pageof 23

Showing results (111-120 of 222) with videos related to

Sort By:
Pageof 23
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 19, 2013
Shedding of HIV and human herpesviruses in the semen of effectively treated HIV-1-infected men who have sex with menSara Gianella, Davey M Smith, Milenka V Vargas, et al.
Journal of Virology|January 18, 2008
Primary human immunodeficiency virus type 1 (HIV-1) infection during HIV-1 Gag vaccinationArumugam Balamurugan, Martha J Lewis, Christina M R Kitchen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 21, 2013
Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabineKimberly Y Smith, Camlin Tierney, Katie Mollan, et al.
AIDS (London, England)|July 4, 2006
Cognitive-behavioral intervention to enhance adherence to antiretroviral therapy: a randomized controlled trial (CCTG 578)Glenn J Wagner, David E Kanouse, Daniela Golinelli, et al.
Virology|September 12, 2006
Lack of neutralizing antibody response to HIV-1 predisposes to superinfectionDavey M Smith, Matthew C Strain, Simon D W Frost, et al.
AIDS Research and Therapy|April 8, 2025
Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIVEric S Daar, Chloe Orkin, Paul E Sax, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 23, 2020
Initiation of Antiretroviral Therapy in the Hospital Is Associated With Linkage to Human Immunodeficiency Virus (HIV) Care for Persons Living With HIV and Substance Use DisorderPetra Jacobs, Daniel J Feaster, Yue Pan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 17, 2018
Safety and Impact of Low-dose Methotrexate on Endothelial Function and Inflammation in Individuals With Treated Human Immunodeficiency Virus: AIDS Clinical Trials Group Study A5314Priscilla Y Hsue, Heather J Ribaudo, Steven G Deeks, et al.
The Journal of Infectious Diseases|June 27, 2013
Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248Adriana Andrade, Susan L Rosenkranz, Anthony R Cillo, et al.
AIDS (London, England)|April 23, 2008
Comparison of algorithms that interpret genotypic HIV-1 drug resistance to determine the prevalence of transmitted drug resistanceLin Liu, Susanne May, Douglas D Richman, et al.
Pageof 23